STAT3 and plasma cell myeloma: Interleukin-6 (IL-6), a known growth factor for MM 35, promote the tumor progression via activating the JAK-STAT3 pathway 36, facilitating the adhesion of myeloma cells to bone marrow mesenchymal stem cells 37 and obstructing dexamethasone-induced apoptosis 38.